Research
Hormonal
In patients with cardiometabolic HFpEF, tirzepatide showed a 58% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.
Tirzepatide may also be a beneficial treatment option for patients with HFpEF and cardiometabolic conditions.
StrongSupportsmedium confidence
Initiators of tirzepatide (HR, 0.42 [95% CI, 0.31-0.57])...had substantially lower risk of the primary end point compared with sitagliptin.
Why this rating
Based on the use of cohort studies with a large sample size.
Source
Semaglutide and Tirzepatide in Patients With Heart Failure With Preserved Ejection Fraction
Nils Krüger et al. · JAMA · 2025
DOI 10.1001/jama.2025.14092
cohort · n=58333Cited 33×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
- In patients with cardiometabolic HFpEF, semaglutide showed a 42% lower risk of hospitalization for heart failure or all-cause mortality compared with sitagliptin.Strong
- Tirzepatide showed no meaningful benefit over semaglutide in reducing the risk of hospitalization for heart failure or all-cause mortality.Strong
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →